Foveal Remodeling of Retinal Microvasculature in Parkinson's Disease.

Parkinson’s disease angiography biomarker capillary density neurodegeneration optical coherence tomography retina

Journal

Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481

Informations de publication

Date de publication:
2021
Historique:
received: 12 05 2021
accepted: 11 06 2021
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 30 7 2021
Statut: epublish

Résumé

Retinal microvascular alterations have been previously described in Parkinson's disease (PD) patients using optical coherence tomography angiography (OCT-A). However, an extensive description of retinal vascular morphological features, their association with PD-related clinical variables and their potential use as diagnostic biomarkers has not been explored. We performed a cross-sectional study including 49 PD patients (87 eyes) and 40 controls (73 eyes). Retinal microvasculature was evaluated with Spectralis OCT-A and cognitive status with Montreal Cognitive Assessment. Unified PD Rating Scale and disease duration were recorded in patients. We extracted microvascular parameters from superficial and deep vascular plexuses of the macula, including the area and circularity of foveal avascular zone (FAZ), skeleton density, perfusion density, vessel perimeter index, vessel mean diameter, fractal dimension (FD) and lacunarity using Python and MATLAB. We compared the microvascular parameters between groups and explored their association with thickness of macular layers and clinical outcomes. Data were analyzed with General Estimating Equations (GEE) and adjusted for age, sex, and hypertension. Logistic regression GEE models were fitted to predict diagnosis of PD versus controls from microvascular, demographic, and clinical data. The discrimination ability of models was tested with receiver operating characteristic curves. FAZ area was significantly smaller in patients compared to controls in superficial and deep plexuses, whereas perfusion density, skeleton density, FD and lacunarity of capillaries were increased in the foveal zone of PD. In the parafovea, microvascular parameters of superficial plexus were associated with ganglion cell-inner plexiform layer thickness, but this was mainly driven by PD with mild cognitive impairment. No such associations were observed in controls. FAZ area was negatively associated with cognition in PD (non-adjusted models). Foveal lacunarity, combined with demographic and clinical confounding factors, yielded an outstanding diagnostic accuracy for discriminating PD patients from controls. Parkinson's disease patients displayed foveal microvascular alterations causing an enlargement of the vascular bed surrounding FAZ. Parafoveal microvascular alterations were less pronounced but were related to inner retinal layer thinning. Retinal microvascular abnormalities helped discriminating PD from controls. All this supports OCT-A as a potential non-invasive biomarker to reveal vascular pathophysiology and improve diagnostic accuracy in PD.

Sections du résumé

BACKGROUND BACKGROUND
Retinal microvascular alterations have been previously described in Parkinson's disease (PD) patients using optical coherence tomography angiography (OCT-A). However, an extensive description of retinal vascular morphological features, their association with PD-related clinical variables and their potential use as diagnostic biomarkers has not been explored.
METHODS METHODS
We performed a cross-sectional study including 49 PD patients (87 eyes) and 40 controls (73 eyes). Retinal microvasculature was evaluated with Spectralis OCT-A and cognitive status with Montreal Cognitive Assessment. Unified PD Rating Scale and disease duration were recorded in patients. We extracted microvascular parameters from superficial and deep vascular plexuses of the macula, including the area and circularity of foveal avascular zone (FAZ), skeleton density, perfusion density, vessel perimeter index, vessel mean diameter, fractal dimension (FD) and lacunarity using Python and MATLAB. We compared the microvascular parameters between groups and explored their association with thickness of macular layers and clinical outcomes. Data were analyzed with General Estimating Equations (GEE) and adjusted for age, sex, and hypertension. Logistic regression GEE models were fitted to predict diagnosis of PD versus controls from microvascular, demographic, and clinical data. The discrimination ability of models was tested with receiver operating characteristic curves.
RESULTS RESULTS
FAZ area was significantly smaller in patients compared to controls in superficial and deep plexuses, whereas perfusion density, skeleton density, FD and lacunarity of capillaries were increased in the foveal zone of PD. In the parafovea, microvascular parameters of superficial plexus were associated with ganglion cell-inner plexiform layer thickness, but this was mainly driven by PD with mild cognitive impairment. No such associations were observed in controls. FAZ area was negatively associated with cognition in PD (non-adjusted models). Foveal lacunarity, combined with demographic and clinical confounding factors, yielded an outstanding diagnostic accuracy for discriminating PD patients from controls.
CONCLUSION CONCLUSIONS
Parkinson's disease patients displayed foveal microvascular alterations causing an enlargement of the vascular bed surrounding FAZ. Parafoveal microvascular alterations were less pronounced but were related to inner retinal layer thinning. Retinal microvascular abnormalities helped discriminating PD from controls. All this supports OCT-A as a potential non-invasive biomarker to reveal vascular pathophysiology and improve diagnostic accuracy in PD.

Identifiants

pubmed: 34321998
doi: 10.3389/fnins.2021.708700
pmc: PMC8311167
doi:

Types de publication

Journal Article

Langues

eng

Pagination

708700

Informations de copyright

Copyright © 2021 Murueta-Goyena, Barrenechea, Erramuzpe, Teijeira-Portas, Pengo, Ayala, Romero-Bascones, Acera, Del Pino, Gómez-Esteban and Gabilondo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Sci Rep. 2018 Jun 20;8(1):9380
pubmed: 29925927
PLoS One. 2020 Jun 3;15(6):e0233975
pubmed: 32492054
Prog Retin Eye Res. 2021 Feb 25;:100954
pubmed: 33640465
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4115-4122
pubmed: 30098201
Invest Ophthalmol Vis Sci. 2012 Aug 17;53(9):5728-36
pubmed: 22836777
Curr Opin Neurol. 2021 Apr 1;34(2):246-257
pubmed: 33630769
Acta Neurol Scand. 2014 May;129(5):307-18
pubmed: 24117192
Parkinsonism Relat Disord. 2017 Jul;40:1-10
pubmed: 28284903
J Neural Transm (Vienna). 2012 Jan;119(1):59-71
pubmed: 21748523
Neurology. 2004 Jan 27;62(2):177-80
pubmed: 14745050
Radiology. 2017 Dec;285(3):885-895
pubmed: 28696183
Sci Rep. 2021 Jan 19;11(1):1847
pubmed: 33469106
JAMA Ophthalmol. 2017 Mar 1;135(3):259-262
pubmed: 28097291
Alzheimers Res Ther. 2020 Dec 4;12(1):161
pubmed: 33276820
Int J Neurosci. 2020 May 4;:1-7
pubmed: 32329398
Quant Imaging Med Surg. 2020 Oct;10(10):1930-1939
pubmed: 33014726
Mov Disord. 2020 Feb;35(2):349-354
pubmed: 31710400
PLoS One. 2012;7(4):e34823
pubmed: 22536333
Neuroreport. 2006 May 15;17(7):705-9
pubmed: 16641673
J Parkinsons Dis. 2015;5(4):821-36
pubmed: 26444086
Mov Disord. 2019 Sep;34(9):1315-1324
pubmed: 31136022
JAMA Ophthalmol. 2021 Feb 1;139(2):182-188
pubmed: 33355613
PLoS One. 2019 Feb 22;14(2):e0212364
pubmed: 30794594
Nat Rev Neurol. 2017 Apr;13(4):217-231
pubmed: 28257128
Ann Neurol. 2020 Nov;88(5):893-906
pubmed: 32881029
Biomed Opt Express. 2013 Jun 14;4(7):1133-52
pubmed: 23847738
Sci Rep. 2017 Feb 10;7:42201
pubmed: 28186181
Brain Pathol. 2013 Mar;23(2):154-64
pubmed: 22897695
Nat Rev Neurosci. 2002 Dec;3(12):932-42
pubmed: 12461550
Int J Ophthalmol. 2018 Nov 18;11(11):1784-1795
pubmed: 30450309
Front Neurol. 2020 Oct 07;11:533375
pubmed: 33117254
Ann Neurol. 2021 Jan;89(1):165-176
pubmed: 33098308
J Anat. 2005 Apr;206(4):319-48
pubmed: 15817102
J Neural Transm (Vienna). 2019 Dec;126(12):1695-1699
pubmed: 31630254
Alzheimers Dement (Amst). 2018 Nov 03;10:773-781
pubmed: 30505927
Ann Clin Transl Neurol. 2015 Feb;2(2):196-201
pubmed: 25750923
Cornea. 2018 Apr;37(4):448-454
pubmed: 29373337
Sci Rep. 2020 Jul 24;10(1):12409
pubmed: 32710087
Biomed Opt Express. 2017 Feb 23;8(3):1741-1753
pubmed: 28663862
PLoS One. 2016 Aug 15;11(8):e0161136
pubmed: 27525728
Parkinsonism Relat Disord. 2019 Jul;64:40-49
pubmed: 31054866
Neurology. 2009 Mar 31;72(13):1121-6
pubmed: 19020293
Retina. 2020 Aug;40(8):1483-1491
pubmed: 31479087
Mov Disord. 2018 Aug;33(8):1315-1324
pubmed: 29737566
J Alzheimers Dis. 2010;21(3):725-39
pubmed: 20634580

Auteurs

Ane Murueta-Goyena (A)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Department of Preventive Medicine and Public Health, University of the Basque Country (UPV/EHU), Leioa, Spain.

Maitane Barrenechea (M)

Biomedical Engineering Department, Faculty of Engineering, Mondragon Unibertsitatea (MU-ENG), Mondragon, Spain.

Asier Erramuzpe (A)

Biomedical Engineering Department, Faculty of Engineering, Mondragon Unibertsitatea (MU-ENG), Mondragon, Spain.

Sara Teijeira-Portas (S)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Marta Pengo (M)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Unai Ayala (U)

Biomedical Engineering Department, Faculty of Engineering, Mondragon Unibertsitatea (MU-ENG), Mondragon, Spain.

David Romero-Bascones (D)

Biomedical Engineering Department, Faculty of Engineering, Mondragon Unibertsitatea (MU-ENG), Mondragon, Spain.

Marian Acera (M)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Rocío Del Pino (R)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Juan Carlos Gómez-Esteban (JC)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Neurology Department, Cruces University Hospital, Barakaldo, Spain.
Department of Neurosciences, University of the Basque Country (UPV/EHU), Leioa, Spain.

Iñigo Gabilondo (I)

Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Neurology Department, Cruces University Hospital, Barakaldo, Spain.
Ikerbasque: The Basque Foundation for Science, Bilbao, Spain.

Classifications MeSH